LeMaitre Vascular re-upped its European distribution deal with Endologix in 12 European nations.
The Burlington, Mass.-based vascular device maker said it will continue to distribute the Endologix Powerlink bifurcated stent graft through June 30, 2013. The previous deal, which was set to expire Dec. 31, 2010, has been in place since 2007.
Chairman and CEO George LeMaitre said the Irvine, Calif.-based company’s stent graft is complements his firm’s TAArget thoracic and UniFit abdominal endografts.
LeMaitre posted its third profitable quarter in a row during the three months ended June 30, reporting $925,000 in second-quarter net income on $12.6 million in sales. That compares with a $926,000 net loss during the year-ago period, when LeMaitre generated $12.7 million in sales.